IP Library Patent Application 14939127
Patent Application
App. No. 14/939,127

METHODS OF TREATING UREA CYCLE DISORDERS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/939,127
Abstract

The present disclosure provides novel methods for determining an effective dosage of a PAA prodrug and for treating a UCD that incorporate body surface area and urinary PAGN concentration. The disclosure further provides novel methods for assessing compliance with PAA prodrug administration that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, or age. The disclosure further provides novel methods of treating a UCD in a subject in need thereof that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, and/or age.

Claims (12)

1 .- 13 . (canceled)

14 . A method of treating a urea cycle disorder (UCD) in a subject in need thereof comprising:

classifying the subject into a body surface area (BSA) group based on the subject's BSA level;

determining a urinary phenylacetylglutamine (PAGN) level for the subject;

comparing the urinary PAGN level to a predetermined threshold urinary PAGN level; and

administering a dosage of a PAA prodrug to the subject if the urinary PAGN level for the subject is below the predetermined threshold urinary PAGN level.

15 . The method of claim 14 , wherein the predetermined threshold urinary PAGN level is a 25th percentile urinary PAGN level for the subject's BSA group.

16 . The method of claim 15 , wherein the subject's BSA group is less than or equal to 1.3 m 2 or greater than 1.3 m 2 .

17 . The method of claim 16 , wherein the 25th percentile urinary PAGN level is about 8390 μg/mL for the less than or equal to 1.3 m 2 BSA group; and the 25th percentile urinary PAGN level is about 5259 μg/mL for the greater than 1.3 m 2 BSA group.

18 . The method of claim 16 , wherein the 25th percentile urinary PAGN level is about 8000 μg/mL for the less than or equal to 1.3 m 2 BSA group; and the 25th percentile urinary PAGN level is about 5000 μg/mL for the greater than 1.3 m 2 BSA group.

19 . The method of claim 16 , wherein the subject is 2 years of age or older and the 25th percentile urinary PAGN level is about 7412 μg/mL for the less than or equal to 1.3 m 2 BSA group.

20 . The method of claim 16 , wherein the subject is 2 years of age or older and the 25th percentile urinary PAGN level is about 7000 μg/mL for the less than or equal to 1.3 m 2 BSA group.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE TWO PATENT NUMBERS PREVIOUSLY RECORDED AT REEL: 039640 FRAME: 0886. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Apr 17, 2017
From: HORIZON THERAPEUTICS INC.
To: HORIZON THERAPEUTICS, LLC
Reel/Frame 043156/0175 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2017
From: SCHARSCHMIDT, BRUCE; MOKHTARANI, MASOUD
To: HYPERION THERAPEUTICS, INC.
Reel/Frame 041646/0440 →
MERGER Recorded Mar 20, 2017
From: HYPERION THERAPEUTICS, INC.
To: HORIZON THERAPEUTICS, INC.
Reel/Frame 041646/0591 →
CHANGE OF NAME Recorded Aug 26, 2016
From: HORIZON THERAPEUTICS, INC.
To: HORIZON THERAPEUTICS, LLC
Reel/Frame 039640/0886 →
CHANGE OF NAME Recorded Aug 9, 2016
From: HORIZON THERAPEUITCS, INC.
To: HORIZON THERAPEUTICS, LLC
Reel/Frame 039633/0851 →